Skip to content
drillr.ai
Sign up

01099.HK

Sinopharm Group Co. Ltd.

HKSE · Healthcare · Medical - Distribution · CN

HKD 15.92
−0.25%
Ask drillr

  • Oct 26, 2026, 07:49 UTC

    Sinopharm Group Co., Ltd. reported third-quarter 2026 revenue of RMB144.8 billion, operating profit of RMB3.635 billion and net profit of RMB1.91 billion, down 0.4%, up 6.2% and up 3.7% year over year, respectively.

    Source:

  • Oct 26, 2026, 04:12 UTC

    Hong Kong-listed shares showed mixed moves at the half-day close, with Meituan up 3.1% and China Life Insurance up 6.1%, while Zijin Mining fell 5.8%.

    Source:

  • Oct 25, 2026, 23:59 UTC

    Sinopharm Group Co., Ltd. reported net profit of RMB 5.31 billion for the nine months, unchanged from the same period a year earlier.

    Source:

  • Oct 25, 2026, 23:57 UTC

    Sinopharm Group Co., Ltd. reported operating revenue of RMB 427.61 billion for nine months.

    Source:

  • Oct 21, 2026, 06:22 UTC

    Sinopharm Group reported that subsidiary Sinopharm Group Co., Ltd. failed to repay bank loans totaling RMB 28.76 million when due.

    Source:

  • Oct 21, 2026, 04:12 UTC

    Hong Kong-listed stocks showed mixed moves at the half-day close, with Contemporary Amperex Technology falling 10.1% and Bright Future Technology and Crystal International reaching record highs.

    Source:

  • Oct 14, 2026, 08:12 UTC

    Hong Kong-listed shares showed varied moves, led by gains in Meituan, Xiaomi and Alibaba and declines in several other active constituents; four stocks reached record highs.

    Source:

  • Sep 8, 2026, 04:06 UTC

    Sinopharm Group and Hansoh Pharmaceutical reached a strategic cooperation agreement, covering broad market, medical access, retail, and DTP special cooperation agreements, upgrading their collaboration to full-chain, full-cycle strategic coordination.

    Source:

  • Aug 26, 2026, 03:20 UTC

    Sinopharm Holding and AstraZeneca launched a special cooperation project on essential medicines in Shanghai, deepening their strategic partnership in pharmaceutical distribution and grassroots healthcare accessibility.

    Source:

  • Aug 25, 2026, 06:22 UTC

    Sinopharm Group's stock fell 3.55% to HK$15.75 on August 25, 2026, after Citi lowered its target price to HK$20.4.

    Source:

  • Aug 17, 2026, 14:52 UTC

    Sinopharm Group's subsidiary China National Accord Medicines reported first-half net profit of 606 million yuan, down 9% year-on-year, with total revenue of 36.266 billion yuan, down 1.4%.

    Source: